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Summary
There has been much controversy concerning the
value of efforts to reduce blood cholesterol levels.
In this contribution, the risks and benefits of
interventions are discussed. Lowering cholesterol
level by drugs is not recommended except in a small
minority of subjects at very high risk of coronary
heart disease (CHD), since it causes an excess of non-
CHD deaths. Dietary intervention, by contrast, is safe.
However, for it to be effective it must be sufficiently
vigorous to achieve a drop in blood cholesterol of at
least 6%, though considerably more is preferable. This
action should be part of a more general effort aimed
at the prevention of all Western diseases based on
changes in lifestyle.
Introduction
Currently, there is controversy over the significance
to health of high and low cholesterol level, whom
should be tested, and over the short and long-term
benefits of interventions'-3. Recent evidence has
indicated that in Western populations there is an
association between a low blood cholesterol level and
death from various diseases, particularly stroke and
certain types of cancer4'5. Among women there is
actually no association between hypercholesterolaemia
and cardiovascular deaths. This is because haem-
orrhagic stroke makes up a higher proportion oftotal
cardiovascular deaths in women, due to their lower
death rates from CHD3.
Ravnskov6 recently reviewed the results from 26
intervention trials in which blood cholesterol had been
lowered by diet or by drugs. He reported that when
all of the trials are taken into account, fatal CHD has
been lowered by only 6% and non-fatal CHD by only
10%. Overall, there has been no change in total
mortality since the fall in fatal CHD is offset by a rise
in fatalities from other causes. Ravnskov contended
that some authors ofreviews and other contributions
have been biased in the literature which they have
cited, thereby leading to the conclusion that the
impact of interventions on CHD has been more
favourable than is actually the case.
The above observations raise the possibility that the
whole strategy to prevent CHD by lowering the blood
cholesterol will achieve, at best, only meagre benefits
since a decrease in CHD will, to a greater or lesser
extent, be offset by a rise in non-CHD deaths.
It is our belief, however, that the lowering of the
blood cholesterol by diet can be recommended for
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the avoidance ofCHD, particularly for the secondary
prevention. Drugs should be reserved for the small
minority of subjects at exceptionally high risk ofCHD.
With this approach the fall in CHD is not outweighed
by an excess of non-CHD mortality. Of course, for
maximal benefit, other aspects of lifestyle in addition
to diet must be incorporated, for alterations in
lifestyle must form part of a general preventive
endeavour against Western diseases. It should be
stressed that efforts in prevention are dwarfed by
those for cure, a fact insufficiently appreciated. To
exemplify, in the UK the health service spends 10
million pounds annually on the prevention of CHD,
but 500 million pounds on treatment7.
Blood cholesterol and CHD
To achieve a clinically meaningful impact on CHD
occurrence there must be a significant reduction in
blood cholesterol. The minimum should be about
6%, but a considerably higher fall is desirable.
Unfortunately, many CHD prevention trials have
achieved only an insignificant decrease in the blood
cholesterol. The major reason for this, as pointed out
by Ramsey et al.8'9, is that a step I diet typically
causes a drop in blood cholesterol of only about 2%.
More rigorous alterations in diet reduce the intake
of fat to supplying 20-30% of energy, and saturated
fat to 5-7%. Such diets achieve a fall of from 6% to
over 20%8,10,11. A step I diet is likely to be effective
when strictly followed; but when supervision is
minimal, as is usually the case in clinical trials, there
is often insufficient compliance'2"3.
Regarding the dietary trials reviewed by Ravnskov6,
five of them achieved a drop in blood cholesterol of
at least 6% and are therefore advantageous. Two
others, that also achieved such a drop in blood
cholesterol, are of limited value as in one ofthe trials
there were only 80 subjects, and in another the trial
lasted only 1.1 years. The odds ratio for CHD in each
ofthe five key trials is shown in Table 1. In none was
there a rise in non-CHD deaths. Taken together the
trials indicate that lowering blood cholesterol does
indeed reduce the risk of CHD. Evidence citable in
support of this conclusion includes the following:
(i) studies on non-human primates demonstrate that
atherosclerosis develops in response to a high blood
cholesterol level, and that lesions regress when the
cholesterol level is lowered19-21; (ii) clinical studies
using angiography indicate that this is also the case
in humans22; (iii) in individuals there is a measure
of association between blood cholesterol and the risk
of CHD; (iv) populations or groups who habitually
consume a diet (and persue a manner of life) that
causes a low blood cholesterol have a low risk of
CHD23'2"; (v) in several European countries, at the
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Table 1. Results from clinical trials
CHD Odds ratio
Trial* Fatal Non-fatal
Research Committee (Ref 14) 0.85 1.17
Leren (Ref 15) 0.68 0.74
MRC soya bean (Ref 16) 0.97 0.72
Dayton et al. (Ref 17) 0.80 -
Oslo Study Group (Ref 18) 0.44 0.61
*The Oslo Study Group trial was multifactorial, the others
were unifactorial
time when wartime changes caused, inter alia, a
reduction in fat and a rise in fibre intake, there was
a fall in mortality from CHD25'26. The evidence cited
constitutes strong support for the concept of a cause
and effect relationship between a high blood cholesterol
and the occurrence of CHD.
There are, however, many perplexing situations
which imply that our understanding ofthe relationship
between diet, blood cholesterol and CHD is still
inadequate. The results of some population studies
appear to conflict with a cause-and-effect relationship
between fat intake, particularly saturated fat, and
CHD27. For instance, France has a mortality rate
from CHD one third ofthat in Scotland, although the
mean cholesterol levels are the same in each country;
this cannot be satisfactorily explained by known risk
factors28. Similarly, Mormons, a religious group who
advocate good health practices but have a typical
American meat intake, have a surprisingly low
mortality from CHD2930. In a contrasting context, in
a group of elderly African women, 5% had a blood
cholesterol about 6.5 mmol/l, yet CHD is unknown
among them31. These discrepant reports emphasize
the need for more research and for caution in making
recommendations. Nevertheless, the desirability of
reducing cholesterol levels would seem a fair decision
from the evidence available.
Non-CHD deaths
Why is the lowering of blood cholesterol often
associated with an increase in non-CHD deaths? The
most likely explanation lies in the use of drugs. Davey
Smith et al.32 reexamined recent evidence and
concluded that drug trials lead to an increase in non-
CHD deaths. In marked contrast, there is no evidence
that adoption of diets which evoke a decrease in
cholesterol level cause an increase in non-CHD
deaths32. This indicates that lowering the blood
cholesterol is not intrinsically dangerous, but rather
that the increase in non-CHD deaths, so often
reported, can be attributed specifically to the use of
drugs.
The safety ofa low blood cholesterol level is strongly
supported by other evidence. All traditionally living
Third World populations have a low average blood
cholesterol level but there is no evidence that on this
account they have an increased risk of stroke, cancer
or of other diseases3334. Similarly, vegetarians in
Western countries have not only a low incidence of
CHD but also have a reduced risk ofother degenerative
diseases. In Germany, for example, in a recent 11-year
prospective study it was reported that the mortality
rate for CHD in vegetarians was only a third of that
in the general population35. Total mortality was
lowered by half. Diseases that were markedly reduced
in frequency were stroke and cancer. The subjects in
that study, beside being vegetarian, were almost all
non-smokers; they tended to be health conscious and
were of a higher socio-economic class. A study
of vegetarians in South Wales yielded similar
observations36. A further example is provided by the
experience of Seventh-Day Adventists, who, besides
being largely vegetarian, are also non-smokers and
largely non-drinkers of alcohol. They have lower rates,
not only ofCHD, but also ofstroke and several cancers
which are common in Western countries (lung and
colon in men; lung, breast and colon in women)37'38.
Clearly, therefore, lowering the blood cholesterol by
dietary means can lower the occurrence ofCHD while
at the same time preventing other diseases and, as
a result, reducing the overall mortality. Why then do
some studies carried out on Western populations
report that individuals who have a low blood
cholesterol also have a raised risk of stroke and of
certain types of cancer? One reason could be the
existence of preclinical disease5. However, this is
unlikely to explain more than a small fraction of
cases4. Another possibility is that such people have
metabolic differences in the manner in which they
process cholesterol. There is also the possibility
that a common factor might cause both a low blood
cholesterol and non-CHD deaths.
The prevention of CHD
Efforts to lower blood cholesterol should continue to
play a major role in the prevention of CHD. But
endeavours, in the great majority of cases, should be
based on rigorous dietary intervention8"10"'1, and not
on drugs. This means that the diet should contain as
little as 20-30% of energy as fat, with 5-7% as
saturated fat. The diet should also include a generous
intake ofplant foods rich in soluble dietary fibre, such
as oats and beans39, unfortunately, both currently
unpopular foods. Such dietary advice can be given
both by physicians to their patients as well as
presented as a public health measure.
The study by Davey Smith et al.32 indicated that
drugs should be used only for those subjects at
exceptionally high risk of CHD. A typical candidate
would be a man with a blood cholesterol exceeding
7.8 mmol/l plus clinically evidence CHD. The prop-
ortions who smoke and have hypertension will increase
the numbers at major risk. In brief, drugs should
normally be reserved for the secondary prevention of
CHD, since in primary prevention an excess of non-
CHD deaths is likely to exceed the number of lives
saved from CHD. As evidence increases from the use
of more modern drugs this position may need to be
revised.
It must be reiterated that there are other major
factors involved in the causation of CHD. Davey
Smith et al.32 insisted that cholesterol levels should
not remain the principal focus of clinical guidelines
aimed at preventing CHD. These factors include
hypertension, smoking, lack of exercise and, to a
lesser extent, obesity. Tunstall-Pedoe and Smith40
have stressed that an elevated cholesterol is far
more noxious in the presence of smoking and
hypertension, since risks are multiplicative, not
additive. Unfortunately, in comparison with the
emphasis placed on lowering the blood cholesterol, the
other factors mentioned have been relatively neglected.
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To repeat, the successful prevention ofCHD demands
a concerted attack on all of these factors, i.e., a
changed lifestyle approach.
The previously mentioned study on German veget-
arians also indicated the superiority of the lifestyle
approach35. In that investigation, the combination of
diet plus a generally healthy lifestyle was associated
with a CHD mortality rate only one-third of that in
the general German population.
It is significant that ofthe trials listed in Table 1 the
multifactorial trial'8 was clearly the most successful.
Also illuminating are the results ofthe World Health
Organization European Collaborative Trial, which
included the study of nearly 61 000 men4l. This trial
involved several lifestyle changes, chiefly of diet,
smoking, weight control and exercise. In addition,
drug treatment was given for hypertension. After six
years of intervention a 10% decrease in CHD was
achieved. Total mortality was reduced by 5.3%. Yet,
even with a trial of this magnitude the resulting
changes were not significant. Bearing in mind the
modest extent ofrisk factor reduction (1.2% for plasma
cholesterol, 8.9% for cigarette consumption, 2% for
systolic blood pressure and 0.4% for weight42, it may
be inferred that a far more pronounced fall in CHD
would have been achieved had the population been
more compliant.
As already emphasized, the altered lifestyle approach
has the outstanding advantage that it is also effective
in preventing other Western diseases in addition to
CHD43. Diseases potentially preventable include
obesity, diabetes, stroke and various cancers. Because
the cost/benefit ratio of a lifestyle approach is so
advantageous, this is likely to make it far more
acceptable to the general public than changes focused
solely on the avoidance ofCHD. Unfortunately, efforts
to persuade the general public to make significant
dietary changes have so far met with very limited
success. As examples, in the Framingham Offspring
Spouse Study44, only 6% to 9% of subjects met total
fat, 9% to 14% saturated fat, and fewer than 3% met
dietary fibre guidelines. In Glasgow, in the MONICA
Study45, only 2% of 'council renters' were eating the
400 g daily of vegetables and fruit recommended by
World Health Organization46. Perhaps the greatest
challenge facing those involved in medicine and
public health is to devise means of influencing people
to change their lifestyle. Endeavours in this respect
should not be abandoned simply because of strong
resistance to change.
Conclusion
A population approach to CHD prevention based on
lowering the blood cholesterol by dietary means is
recommended. There is little to suggest that this will
cause an increase in non-CHD deaths. To achieve a
clinically significant impact on CHD demands a
statistically significant impact on blood cholesterol.
This requires rigorous dietary intervention. To obtain
maximum benefits, the dietary approach must be
combined with a more general intervention targeting
hypertension, obesity, cigarette smoking and lack
of exercise. Such a lifestyle approach should be
'marketed' as a general preventive of Western
diseases.
Dedication: This paper is dedicated to Denis Burkitt
MD FRS FRCS, who died on 23 March 1993.
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European Rheumatologists in Training
(EULAR Standing Committee for Education & Training)
EURORITS was established to improve the interaction between junior rheumatologists in different
European countries and increase their awareness, knowledge and experience of rheumatology as
practised throughout Europe. To enable this, EURORITS will help arrange visits of 1-2 weeks
to centres in other European countries and, if possible, offer a travel bursary. This has been made
available by the Arthritis & Rheumatism Council, EULAR, and the pharmaceutical industry. The
visits can be to any centre of choice, but several departments in various European countries have
been identified who are prepared to occasionally host such visits (details available on request).
Trainee or junior rheumatologists who would like to apply for a travel bursary, please contact Dr
A D Woolf, Chairman, European Rheumatologists in Training, Duke of Cornwall Rheumatology
Unit, Royal Cornwall Hospital (City), Truro TR1 2HZ, UK for an application form and further
details.
